Skip to content
Home
Visit our other Journals
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Diseases
Alzheimer's Disease
Dementia
Dementia with Lewy Bodies
Frontotemporal Dementia
Vascular Dementia
Mild Cognitive Impairment
View all Diseases
Topics
Diagnostics
Biology
Biomarkers
Treatment
Clinical Care
Prevention
View all Topics
Conferences
AAIC 2023
BNA 2023
AD/PD 2023
ARUK 2023
CTAD 2022
AAIC 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Stephen Salloway
6:04
Development of Appropriate Use Recommendations for lecanemab
Stephen Salloway
• 19 Apr 2023
2:36
Prospects for Alzheimer’s disease monitoring and treatment in 2023
Stephen Salloway
• 19 Apr 2023
2:26
Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials
Stephen Salloway
• 19 Apr 2023
2:48
TRAILBLAZER-ALZ 4: direct comparison of donanemab and aducanumab
Stephen Salloway
• 19 Apr 2023
1:50
Safety results of the Phase III gantenerumab GRADUATE I and II studies
Stephen Salloway
• 19 Apr 2023
6:32
Blood biomarkers in Alzheimer’s disease: appropriate use recommendations
Stephen Salloway
• 19 Aug 2022
6:38
Aducanumab updated monitoring recommendations for amyloid-related imaging abnormalities (ARIA)
Stephen Salloway
• 19 Aug 2022
1:23
Updates in pharmacological treatment of Alzheimer’s disease: lecanemab, donanemab and gantenerumab
Stephen Salloway
• 19 Aug 2022
2:57
The potential of plasma biomarkers in dementia
Stephen Salloway
• 13 Aug 2021
3:10
Donanemab: breakthrough therapy designation based on TRAILBLAZER data
Stephen Salloway
• 13 Aug 2021
8:06
Aducanumab: what’s the latest?
Stephen Salloway
• 13 Aug 2021
1:32
Major ongoing clinical trials in AD: aducanumab, donanemab & lecanemab
Stephen Salloway
• 13 Aug 2021